EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  1, 2     Marla C. Dubinsky  3     Bruce E. Sands  3     Julian Panés  4     Stefan Schreiber  5     Walter Reinisch  6     Brian G. Feagan  7, 8     Silvio Danese  9     Andres Yarur  10     Geert R. D'Haens  11     Martina Goetsch  12     Karolina Wosik  13     Joseph Wu  14     Irene Modesto  15     Aoibhinn McDonnell  16     Lauren Bartolome  17     Christopher J. Rabbat  17     Severine Vermeire  18    
1 University of Lorraine, CHRU-Nancy, Nancy, France
2 University of Lorraine, Inserm, NGERE, Nancy, France
3 Icahn School of Medicine at Mount Sinai, New York, United States
4 Formerly Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
5 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
6 Medical University of Vienna, Vienna, Austria
7 Western University, London, Canada
8 Alimentiv Inc, London, Canada
9 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
10 Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, United States
11 Amsterdam University Medical Centers, Amsterdam, Netherlands
12 Pfizer AG, Zürich, Switzerland
13 Pfizer Canada, Kirkland, Canada
14 Pfizer Inc, Groton, United States
15 Pfizer Inc, Madrid, Spain
16 Pfizer Ltd, Sandwich, United Kingdom
17 Pfizer Inc, New York, United States
18 University Hospitals Leuven, Leuven, Belgium

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing